Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

REM-422

ARIA

Remix Therapeutics (merging with Passage Bio) · Phase 1/2 · Recruiting · Enrollment 125

NCT06118086

Catalyst Primary completion. 09.30.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst ENA 2026 late-breaking oral 5LBA (updated Phase 1). 11.19.2026. Company release 10.28.2026.

Catalyst Initial Phase 2 data (company guidance). H1 2027. Company statement: mid-2027.

ArmReported safety
REM-422 24 mg (RP2D), biomarker positiven/r
REM-422 12 mg or more, biomarker positiven/r
REM-422 24 mg, safetytreatment-related epistaxis (all grade 1 or 2): 60%, cutoff 01.07.2026treatment-related fatigue (all grade 1 or 2): 60%, cutoff 01.07.2026
REM-422 Phase 2 confirmatory cohortn/r

A count stays a count. This page does not turn a count into a percent.